Australian Clinical Labs (ACL) Stock Price, News & Analysis

Company Overview

Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals. Australian Clinical Labs Limited was incorporated in 2020 and is headquartered in Clayton, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $728.27 million
• P/E Ratio: 30.38
• Dividend Yield: 3.28%
• Price Target: N/A
• Consensus Rating: N/A

ACL Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Australian Clinical Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Australian Clinical Labs investors own include Allied Gaming & Entertainment (AGAE), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Berkeley Energia (BKY), Global X Cloud Computing ETF (CLOU) and Coles Group (COL).

Company Calendar

• Ex-Dividend for 4/15 Dividend: 3/26/2025
• Record date for 4/15 Dividend: 4/15/2025
• Dividend Payable: 4/15/2025
• Today: 4/28/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: ASX:ACL
• CIK: N/A
• Web: www.clinicallabs.com.au
• Phone: 61 3 9538 6777
• Fax: N/A
• Employees: 5,115
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A$0.12
• Trailing P/E Ratio: 30.38
• Forward P/E Ratio: N/A
• P/E Growth: -0.36
• Net Income: $23.93 million
• Net Margins: 3.45%
• Pretax Margin: N/A
• Return on Equity: 13.98%
• Return on Assets: 6.67%

Debt

• Debt-to-Equity Ratio: 174.00
• Current Ratio: 0.64
• Quick Ratio: 0.53

Sales & Book Value

• Annual Sales: $696.37 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.89 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 201,830,000
• Free Float: N/A
• Market Cap: $728.27 million
• Optionable: Not Optionable
• Beta: 1.18